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In this study, we evaluated an inhibition model of luseogliﬂozin on sodium glucose co-transporter 2
(SGLT2). We also analyzed the binding kinetics of the drug to SGLT2 protein using [3H]-luseogliﬂozin.
Luseogliﬂozin competitively inhibited human SGLT2 (hSGLT2)-mediated glucose uptake with a Ki value
of 1.10 nM. In the absence of glucose, [3H]-luseogliﬂozin exhibited a high afﬁnity for hSGLT2 with a Kd
value of 1.3 nM. The dissociation half-time was 7 h, suggesting that luseogliﬂozin dissociates rather
slowly from hSGLT2. These proﬁles of luseogliﬂozin might contribute to the long duration of action of
this drug.
© 2015 Taisho Pharmaceutical Co., Ltd. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Sodium glucose co-transporters (SGLTs) are a class of proteins
expressed on the membranes of cells in various tissues. SGLT2 is
mainly localized in the S1 and S2 segments of the renal proximal
tubules and mediates the reabsorption of ﬁltered glucose via the
glomeruli. Recently, clinical studies have conﬁrmed the efﬁcacy of
SGLT2 inhibitors in improving glycemic control (1e3), and several
SGLT2 inhibitors are currently available for the treatment of type 2
diabetes (T2DM). Luseogliﬂozin ((1S)-1,5-anhydro-1-[5-(4-
ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol hy-
drate) (Luseﬁ™, Taisho Pharmaceutical Co., Ltd.) is a novel and spe-
ciﬁc SGLT2 inhibitor, and is commercially available as a
pharmaceutical agent to treat T2DM. In a previous study, luseogli-
ﬂozin was demonstrated to inhibit sodium-dependent glucose up-
take in cells stably expressing human SGLT2 (hSGLT2), with an IC50
value of 2.26 nM (4). In preclinical animal models of diabetes,
luseogliﬂozin was shown to enhance urinary glucose excretion and
reduce the severity of hyperglycemia (5). Although the IC50 value of
luseogliﬂozin for SGLT2 in vitro was similar to that of commercially
available SGLT2 inhibitors thathavebeenused to treat T2DM, clinical
studies in Japanese patients with T2DMhave shown that once-dailys, Taisho Pharmaceutical Co.,
a 331-9530, Japan. Tel.: þ81
kahashi).
rmacological Society.
duction and hosting by Elsevier B.V
g/licenses/by-nc-nd/4.0/).administration of luseogliﬂozin, even at a very low dose (0.5 mg),
leads to signiﬁcant improvement of the HbA1c levels (1). In healthy
Japanese subjects, luseogliﬂozin-induced dose-dependent increases
in urinary glucose excretion were observed for at least 48 h after a
single administration of 1e25 mg (6).
In the present study, we investigated the SGLT2 inhibition
kinetics of luseogliﬂozin against sodium-dependent glucose uptake
in Chinese hamster ovary-K1 cells stably expressing hSGLT2 to
evaluate an inhibition model for glucose transport. We employed
the [3H]-luseogliﬂozineSGLT2 binding assay to investigatewhether
luseogliﬂozinmight bind speciﬁcally to the SGLT2protein expressed
on the membranes of cells.
Methods to prepare cells stably expressing hSGLT2 and glucose
uptake study were described in a previous study (5). The cells were
incubated in 75 mL of sodium buffer (140mMNaCl, 2 mMKCl, 1 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES, 5 mM Tris, pH 7.2e7.4) con-
taining 1, 2, 4, 8 or 16 mM of the methyl-a-D-glucopyranoside
(a-MG) mixture ([14C]-a-MG: PerkinElmer, Tokyo and unlabeled
a-MG: SigmaeAldrich, St. Louis, MO, USA) and 1, 2 or 4 nM of
luseogliﬂozin (Taisho Pharmaceutical Co., Ltd., Saitama) or
dimethyl sulfoxide vehicle at 37 C for 60 min; each of the in-
cubations was performed in triplicate.
Binding assays were performed using a modiﬁcation of the
method of Grempler (7). For the saturation binding experiments,
cell membranes (60 mg/well) were incubated with 1.3e368.8 nM
[3H]-luseogliﬂozin (Quotient Bioresearch Ltd., Cardiff, UK) in assay. on behalf of Japanese Pharmacological Society. This is an open access article under
Fig. 1. Kinetic analysis of the inhibition of hSGLT2 by luseogliﬂozin. Cells stably
expressing hSGLT2 were incubated in sodium buffer containing various concentrations
of an a-MG mixture ([14C]-a-MG and unlabeled a-MG) and luseogliﬂozin at 37 C for
60 min. Sodium-dependent a-MG uptake was calculated by subtracting radioactivity
(cpm) in the absence of sodium from radioactivity in the presence of sodium. The
inhibition pattern was analyzed by LineweavereBurk plots. The data points represent
the mean of three wells from a single representative experiment.
Fig. 2. Analysis of the binding kinetics of [3H]-luseogliﬂozin to hSGLT2 protein. A and B) Satu
hSGLT2 cells were incubated with [3H]-luseogliﬂozin in an assay buffer in the absence and p
wells from a single representative experiment. C and D) Association and dissociation curves
association time-course experiments, membranes were incubated with [3H]-luseogliﬂozin
experiments, after 12 h incubation with [3H]-luseogliﬂozin, unlabeled luseogliﬂozin was ad
represent the mean ± SEM of three experiments.
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presence of glucose (20 mM, Wako Pure Chemical Industries Ltd.,
Osaka), respectively, for 6 h at 25 C in 96-well plates. For the as-
sociation experiments, membranes were incubated with 5.2 and
19 nM of [3H]-luseogliﬂozin in the absence and presence of glucose
(20 mM), respectively, for 0.25, 1, 3, 6, 9 and 12 h at 25 C. For the
dissociation experiments, 12 h after association, 760 and 1970 nM
of unlabeled luseogliﬂozin, approximately 100 times the amount of
[3H]-luseogliﬂozin, in the absence and presence of glucose,
respectively, were added, followed by incubation for 2, 4, 7.67, 18.5
and 30 h at 25 C. The approximate Kd values calculated from the
saturation binding experiments were used as the concentrations
for [3H]-luseogliﬂozin in the presence or absence of glucose.
Nonspeciﬁc binding was determined with 50 mM of phlorizin
(SigmaeAldrich). The data were analyzed using GraphPad Prism
5.04 (GraphPad Software, Inc., La Jolla, CA, USA).
In this study, we investigated the inhibitory kinetics of luseo-
gliﬂozin for SGLT2, to elucidate the mechanism of SGLT2 inhibition.
According to the LineweavereBurk analysis (Fig. 1), luseogliﬂozin
competitively inhibited SGLT2-mediated sodium-dependent
glucose uptake, and calculation based on Dixon plots yielded a Ki
value of 1.10 nM (95% conﬁdence interval: 1.01e1.18 nM).
Speciﬁc binding of [3H]-luseogliﬂozin to the membranes of
hSGLT2-expressing cells was saturated at 50 nM of [3H]-luseogli-
ﬂozin (Fig. 2A). Scatchard analysis of the binding of luseogliﬂozin toration curve and Scatchard plot of [3H]-luseogliﬂozin binding to hSGLT2. Membranes of
resence of glucose (20 mM) for 6 h at 25 C. The data points represent the mean of two
of [3H]-luseogliﬂozin binding to hSGLT2 in the absence and presence of glucose. For the
[5.2 nM (C) and 19 nM (D)] for 0.25e12 h at 25 C. For the dissociation time-course
ded in excess [760 nM (C) or 1970 nM (D)] and incubated for 2e30 h at 25 C. Data
Table 1
Kinetic binding data of [3H]-luseogliﬂozin for hSGLT2 in the absence and presence of 20 mM glucose.
() glucose 20 mM glucose
Mean ± SE Mean ± SE
Kd (nM) 1.3 ± 0.13 7.0 ± 0.70
Kon (M1 $ min1) 1.4  106 ± 1.5  105 2.4  105 ± 6.9  103
Koff (min1) 1.8  103 ± 5.4  105 1.7  103 ± 1.6  104
Dissociation half-time (min) 420 ± 10 430 ± 39
Each of the values was calculated from the association and dissociation curves. Data represent the mean ± SEM of three experiments.
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that [3H]-luseogliﬂozin binds to one site on hSGLT2 protein in the
absence and presence of glucose (20 mM). The time-course of the
association and dissociation for speciﬁc binding of [3H]-luseogli-
ﬂozin to the membranes of cells stably expressing hSGLT2 is shown
in Fig. 2C and D. The association for speciﬁc binding of [3H]-
luseogliﬂozin approached a plateau after approximately 12 h. After
addition of unlabeled luseogliﬂozin at approximately 100 times the
amount of [3H]-luseogliﬂozin, the radioligand gradually dissociated
from hSGLT2, with almost complete dissociation occurring by
approximately 30 h in both the absence and presence of glucose
(20 mM). The values of Kon were 1.4  106 M1 $ min1 and
2.4  105 M1 $ min1 in the absence and presence of glucose
(20 mM), respectively. The value of Kon in the presence of glucose
was lower than that in the absence of glucose, consistent with the
competitive inhibition model of luseogliﬂozin. On the other hand,
the values of Koff in both the absence and presence of glucose were
in the same order (1.8  103 min1 and 1.7  103 min1,
respectively). Then, the Kon and Koff values were used to calculate
the dissociation half-time and Kd values. In the absence and pres-
ence of glucose (20 mM), the dissociation half-time were 420 and
430 min, respectively. Based on the Kon and Koff values, [3H]-
luseogliﬂozin exhibited a high afﬁnity for SGLT2 in the absence of
glucose, with a Kd value of 1.3 nM. In the presence of glucose, the
afﬁnity for SGLT2 was slightly lower, with a Kd value of 7.0 nM
(Table 1).
Luseogliﬂozin, a structurally novel C-5-thioglucoside, is a potent
inhibitor of SGLT2 with an IC50 value of 2.26 nM, and exhibits a
1765-fold selectivity for hSGLT2 as compared to hSGLT1 (5).
Recently, several SGLT2 inhibitors have been developed for the
control of hyperglycemia in patients with T2DM. Sergliﬂozin (O-
glucoside) developed earlier and tofogliﬂozin (O-spiroketal C-
glucoside) developed later have been shown to be competitive
SGLT2 inhibitors (8,9). Thus, the present study demonstrates that
the mechanism of SGLT2 inhibition by a C-5-thioglucoside, luseo-
gliﬂozin, is similar to that of the O- and C-glucosides.
Recent report indicates that there is a possibility that sugar
moiety of a selective SGLT2 inhibitor, dapagliﬂozin, binds in the
glucose binding site (10). The Kd value of luseogliﬂozin for SGLT2 in
the presence of a high glucose concentration (20 mM) was larger
than that in the absence of glucose, which suggested that luseo-
gliﬂozin was a competitive SGLT2 inhibitor. Furthermore, the Kd
value in the absence of glucose was the same as the Ki value of
SGLT2 inhibition in the inhibitory kinetics study.
Our study also revealed that the dissociation half-time of
luseogliﬂozinehSGLT2 binding was approximately 7 h. On the
other hand, phlorizin, a non-selective SGLT inhibitor, has been re-
ported to show short-acting inhibition, with a half-time of phlor-
izinehSGLT2 binding of 24 s (11). Recently, empagliﬂozin, a novel C-
glucoside, was shown as a slow-dissociating SGLT2 inhibitor with a
half-time of empagliﬂozinehSGLT2 binding of approximately
60min (7). Although the reasons for these differences in the rates of
dissociation of the inhibitors have not yet been determined, thedissociation of luseogliﬂozin from hSGLT2 appears to be much
slower than that of phlorizin or empagliﬂozin.
In a previous study, we demonstrated that luseogliﬂozin was
present at an approximately 35-fold concentration in the kidney as
compared to that in the plasma at 4 h after oral administration in
rats, indicating that appreciable amounts of luseogliﬂozin are
distributed to the target organ (4). In healthy Japanese subjects,
luseogliﬂozin-induced dose-dependent increases in urinary glucose
excretion were observed for at least 48 h after a single administra-
tion at all doses tested, although themean plasma concentrations of
luseogliﬂozin had decreased to 2e3% of maximum plasma level or
lower (6). These results are in agreement with the much slower
dissociation of the luseogliﬂozinehSGLT2 complex. It is thought
that there is a possibility of luseogliﬂozin binding to SGLT2 in the
kidney after the disappearance of the drug from the plasma.
It still remains unclear whether luseogliﬂozin binds to extra-
cellular or intracellular site of SGLT2. Our previous study demon-
strates that luseogliﬂozin shows moderate Caco-2 cell permeability
(4) and might accumulate in the proximal tubular cells. However,
previous report indicates that phlorizin and a speciﬁc SGLT2 in-
hibitor, TA-3404, inhibit SGLT2 by acting from the extracellular site
of the plasma membrane (12). Based on these ﬁndings, it seems
that, like phlorizin, luseogliﬂozin inhibits SGLT2 by acting from the
extracellular side. Additional experiments are required to resolve
this question.
In conclusion, luseogliﬂozin is a highly potent and competitive
inhibitor of SGLT2, and speciﬁcally binds to SGLT2. Furthermore,
the results of the present study indicated that the dissociation of
luseogliﬂozin from SGLT2 occurs very slowly. The results suggest
that the binding kinetics of luseogliﬂozin to SGLT2 localized in the
S1 and S2 segments of the renal proximal tubules may contribute to
the sustained pharmacological effect of this drug.
Conﬂicts of interest
All authors are employees of Taisho Pharmaceutical Co., Ltd., and
there are no known conﬂicts of interest associated with this
publication.
Acknowledgments
We thank Dr. Eiichi Kunioka and Mr. Naoki Kojima for their
support.
References
(1) Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efﬁcacy and safety of
luseogliﬂozin monotherapy in Japanese patients with type 2 diabetes melli-
tus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res
Opin. 2014;30:1219e1230.
(2) Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efﬁcacy and
safety of canagliﬂozin in Japanese patients with type 2 diabetes: a random-
ized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab.
2013;15:1136e1145.
S. Uchida et al. / Journal of Pharmacological Sciences 128 (2015) 54e57 57(3) List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport
inhibition with dapagliﬂozin in type 2 diabetes. Diabetes Care. 2009;32:
650e657.
(4) Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, Arai M, Kawakita Y, Fukasawa Y,
et al. (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-
1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose
cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem.
2010;53:3247e3261.
(5) Yamamoto K, Uchida S, Kitano K, Fukuhara N, Okumura-Kitajima L, Gunji E,
et al. TS-071 is a novel, potent and selective renal sodium-glucose cotrans-
porter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol.
2011;164:181e191.
(6) Sasaki T, Seino Y, Fukatsu A, Sakai S, Samukawa Y. Safety, pharmacokinetics,
and pharmacodynamics of single and multiple luseogliﬂozin dosing in healthy
Japanese males: a randomized, single-blind, placebo-controlled trial. Adv
Ther. 2014;31:345e361.
(7) Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al.
Empagliﬂozin, a novel selective sodium glucose cotransporter-2 (SGLT-2)inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Diabetes Obes Metab. 2012;14:83e90.
(8) Pajor AM, Randolph KM, Kerner SA, Smith CD. Inhibitor binding in the human
renal low- and high-afﬁnity Naþ/glucose cotransporters. J Pharmacol Exp
Ther. 2008;324:985e991.
(9) Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, et al. Tofogli-
ﬂozin, a potent and highly speciﬁc sodium/glucose cotransporter 2 inhibitor,
improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther.
2012;341:692e701.
(10) Hummel CS, Lu C, Liu J, Ghezzi C, Hirayama BA, Loo DD, et al. Structural
selectivity of human SGLT inhibitors. Am J Physiol Cell Physiol. 2012;302:
C373eC382.
(11) Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose
transport by human renal Naþ/D-glucose cotransporters SGLT1 and SGLT2.
Am J Physiol Cell Physiol. 2011;300:C14eC21.
(12) Ghezzi C, Hirayama BA, Gorraitz E, Loo DD, Liang Y, Wright EM. SGLT2 in-
hibitors act from the extracellular surface of the cell membrane. Physiol Rep.
2014;2:e12058.
